Extended Data Fig. 5: Five-year survival analysis of patients with or without BRAF mutation for the confirmation-cohort OpACIN-neo. | Nature Medicine

Extended Data Fig. 5: Five-year survival analysis of patients with or without BRAF mutation for the confirmation-cohort OpACIN-neo.

From: Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial

Extended Data Fig. 5

a-e, Kaplan Meier curves, including log-rank P value, sub grouped according to presence / absence of BRAF-V600E/K mutation for event free survival BRAF-mutant (n = 37) versus BRAF-wildtype (n = 36) (a), relapse-free survival in BRAF-mutant (n = 35) versus BRAF-wildtype (n = 35) (b), distant metastases-free survival in BRAF-mutant (n = 35) versus BRAF-wildtype (n = 35) (c), overall survival in BRAF-mutant (n = 37) versus BRAF-wildtype (n = 36) (d), and melanoma specific survival in BRAF-mutant (n = 36) versus BRAF-wildtype (n = 34) (from registration to melanoma related death) (e). f,g, Kaplan Meier curves including log-rank P value, per based on their BRAF mutational status and treatment-arm (arm A (ipilimumab 3 mg kg−1 plus nivolumab 1 mg kg−1) versus arm B (ipilimumab 1 mg kg−1 plus nivolumab 3 mg kg−1)): BRAF-mutant patients treated in arm A (n = 13), BRAF-mutant treated in arm B (n = 12), BRAF-wildtype treated in arm A (n = 13) and BRAF-wildtype treated in arm B (n = 14), for event free survival (f) and overall survival (g).

Back to article page